Please ensure Javascript is enabled for purposes of website accessibility

Why Johnson & Johnson Fell Today Despite Excellent Coronavirus Vaccine News

By Eric Volkman - Jan 29, 2021 at 7:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's vaccine has a lower efficacy rate than others.

What happened

Johnson & Johnson (JNJ -0.57%) closed 3.6% lower on Friday. A downward move is exactly the opposite of what you'd expect to happen when a coronavirus vaccine developer announces positive clinical trial results, as the company did that morning.

So what

Data indicated that Johnson & Johnson's candidate met all of the primary and key secondary endpoints in its phase 3 clinical trial. In the sprawling global study, the vaccine's overall efficacy was 66% in blocking moderate to severe COVID-19. It was 85% effective in preventing severe forms of the disease.

A child getting a vaccine jab from a medical professional.

Image source: Getty Images.

Better yet, the vaccine's "efficacy against severe disease increased over time, with no cases in vaccinated participants reported after day 49," as the company wrote. It also showed complete protection against hospitalization and death from the disease 28 days after vaccination. No significant safety concerns were reported, and the vaccine was well-tolerated.

One advantage of the pharmaceutical giant's vaccine is that it is administered in a single dose, as opposed to the two-shot vaccines currently authorized in the U.S.

Johnson & Johnson plans to file for an emergency use authorization (EUA) from the Food and Drug Administration in early February.

Now what

An inoculation efficacy rate of 66% is not as good as that of the competition. The Moderna and Pfizer/BioNTech vaccines both had significantly higher rates (94.1% and 95%, respectively). Still, 66% is considered to be a strong result. Plus, Johnson & Johnson's testing involved more contagious variants of the coronavirus. Moderna and Pfizer/BioNTech's results came before the spread of those variants.

All in all, this was excellent news for Johnson & Johnson, so the sell-off seems undeserved. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$176.85 (-0.57%) $-1.02
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.92 (-0.93%) $0.47
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$137.91 (5.95%) $7.74
BioNTech SE Stock Quote
BioNTech SE
BNTX
$158.84 (0.53%) $0.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.